RXi Pharmaceuticals Corp.

RXi Pharmaceuticals Corporation is a clinical-stage company developing innovative therapeutics that address significant unmet medical needs. Building on the pioneering discovery of RNAi, the Company's discovery and clinical development programs are based on its proprietary self-delivering RNAi (sd-rxRNA®) platform and Samcyprone™, a small molecule topical immunomodulator. Current clinical development programs include RXI-109, an sd-rxRNA, for the treatment of dermal and ocular scarring, and Samcyprone™ for the treatment of such disorders as warts, alopecia areata, non-malignant skin tumors and cutaneous metastases of melanoma. RXi's robust pipeline, coupled with an extensive patent portfolio, provides for multiple product and business development opportunities across a broad spectrum of therapeutic areas. We are committed to being a partner of choice for academia, small companies, and large multinationals. We welcome ideas and proposals for strategic alliances, including in- and out-licensing opportunities, to advance and further develop strategic areas of interest.

Expert Comments:

With the granting of a new patent in Japan for its lead compound, RXI-109, RXI Pharmaceuticals has strengthened its reach in Asian markets and enhanced the protections surrounding its proprietary RNAi platform.
read more >
Management Q&A: View From the Top
RXi Pharmaceuticals' proprietary self-delivering RNAi (sd-rxRNA) platform offers efficient delivery to cells ex vivo, an application with tremendous potential in immuno-oncology. It's no surprise then that RXi has acquired MirImmune, a company that has been focusing on the next generation of immunotherapies for the treatment of cancer. In this interview with The Life Sciences Report, Geert Cauwenbergh, RXi's President and CEO; Alexey Eliseev, Chief Business Officer; and Pam Pavco, Chief Development Officer, discuss their technologies, the merger and why they believe that in 10 years pure chemotherapy could be relegated to the treatment of last resort.
read more >
Marcel Wijma, Van Leeuwenhoeck Research (2/13/17)
"Based on our net present value valuation, we believe that RXi Pharmaceuticals Corp. is substantially undervalued at the current share price of $0.74. Using our valuation model and taking into account the further development of its pipeline including the acquisition of MirImmune, the company's current total value should be $75-100M, or $4.50-6/share; this represents a substantial upside from the current share price."

Donovan Jones, Seeking Alpha (12/15/16)
"RXi Pharmaceuticals Corp. secured an exclusive option to acquire MirImmune, a company developing cell-based immunotherapies for the treatment of cancers such as ovarian cancer and melanoma. . .for its lead candidate RXI-109 for the treatment of dermal scarring. . .the preliminary data showed positive differentiation between control and treated subjects after surgical incisions at all time points through nine months post-surgery. RXi expects a complete results announcement in mid-2017. . .RXII's offering is a Buy, based on a promising outlook for its leading scar treatment candidate."

By securing an exclusive option to acquire MirImmune Inc., RXi Pharmaceuticals has expanded its reach into the "high-value" field of immuno-oncology, a move that has energized the company and prompted a pair of analysts to express optimism about RXi's future.
read more >
Maxim Jacobs, Edison Investment Research (10/25/16)
"RXi Pharmaceuticals Corp. recently announced that it has entered into an exclusive option agreement to acquire MirImmune, an early-stage private company focusing on immune checkpoint modulation, in exchange for a share amount equal to 19.99% of RXi's outstanding stock plus milestones. . .MirImmune had licensed RXi's sd-rxRNA technology for use in cell-based cancer immunotherapy back in March 2015. . .the knockdown of these proteins should enable the CAR-T cells to recognize and engage tumor cells that are otherwise masked from the immune system via expression of checkpoint ligands."

Keith Markey, Griffin Securities (10/12/16)
"RXi Pharmaceuticals Corp. takes an exclusive option to acquire MirImmune, a privately held company that licensed RXi's self-delivering RNAi technology for cancer indications in early 2015. Execution of the option, which expires on April 5, 2017, would add six sd-rxRNA compounds to the company's pipeline in exchange for equity stake of 19.99% at the closing. . .the acquisition is an attractive opportunity. . .in 2018, clinical development of the oncology-related compounds should commence. . .2016 will likely close in fine fashion."

Keith Markey, Griffin Securities (8/22/16)
"RXi Pharmaceuticals Corp. will report results from human tests of four programs in the next 12 months or so. . .investors will see data from three clinical trials and a proof-of-concept study of a consumer product. Interim data on Samcyprone should be available in November. . .dermal scarring trial of RXI-109 will report results before year end. . .proof-of-concept results on RXI-231 will likely be available next summer. . .news from the R&D pipeline should pique investors’ interest in RXII shares in the months ahead."

Carol Werther, H.C. Wainwright & Co. (6/7/16)
"We Are Assuming Coverage With a Buy Rating. . .RXi Pharmaceuticals Corp.'s RXI-109 is the basis for our recommendation and in our opinion may reach the US market in 2021. . .the discovery of RNAi is regarded as a significant advancement in the scientific community, and in 2006 the Nobel Prize in Medicine was awarded to the co-discoverers of RNAi, including Dr. Craig Mello, one of the founders of RXI and the Chairman of the Scientific Advisory Board. . .we believe RXII shares are undervalued given the compelling RX-109 results in hypertrophic scarring."

More Expert Comments

Experts Following This Company

Maxim Jacobs – Edison Investment Research
Keith Markey, Scientific Director – Griffin Securities
Carol Werther – Summer Street Research Partners
Marcel Wijma, Analyst – The Daily Molecule (Van Leeuwenhoeck Research), Van Leeuwenhoeck Research

The information provided above is from analysts, newsletters, the company and other contributors.

RXi Pharmaceuticals Corp. is a sponsor of Streetwise Reports. The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

The Expert Opinions above are excerpted from third-party sources not affiliated with or controlled by Streetwise Reports. The statements or opinions expressed in the Expert Opinions above are those of the authors indicated, and Streetwise Reports has not verified the accuracy of material excerpted here.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.

Investing Highlights
RXi has developed a robust, proprietary RNAi therapeutic platform
RNAi has the ability to “silence” a specific gene in a disease condition
Extensive patent estate provides for multiple development and commercialization of RNAi therapeutics